Shi L et al. demonstrated that treatment with anti-TSLPR significantly reduced Th2 responses by decreasing the expression of IL-4 and IL-5 in addition to moderately elevating IFN-γ in a mouse model of OVA-induced asthma [22]. This evidence concerns the gene IL5 and asthma.